Novo Nordisk (NVO.US) unveils a $23 billion pipeline blueprint, but the market remains unimpressed! Investors question "how to turn the situation around"

```htmlAccording to Golden Ten Data, Novo Nordisk, the global pharmaceutical giant headquartered in Denmark, plans to launch more than five blockbuster drugs in the next few years. The Danish pharmaceutical company is striving to maintain its competitiveness in the increasingly crowded obesity treatment market. At its Capital Markets Day, Novo Nordisk pledged to launch over five blockbuster drugs and achieve more than $23 billion in additional sales over the next few years. However, its share price plummeted by 7.7% during early European trading. Novo Nordisk’s U.S. ADR (NVO.US) also weakened sharply in U.S. pre-market trading on Monday, falling by over 7% at one point.```